Celldex Therapeutics, Inc. — 2016 Form 10-K Summary
Business context and reporting period. This annual report covers the year ended December 31, 2016; fourth-quarter figures are also reported. Celldex is a clinical-stage biopharmaceutical company developing cancer immunotherapies and targeted biologics. It had no product sales. The November 2016 acquisition of Kolltan added clinical-stage candidates CDX-0158 and CDX-3379 and the TAM antibody program. The financial statements include Kolltan results from November 29 through year-end.
Financial performance and position
| Metric | 2016 | 2015 |
|---|---|---|
| Revenue | $6.8 million | $5.5 million |
| Research and development expense | $102.7 million | $100.2 million |
| Total operating expense | $139.7 million | $135.0 million |
| Operating loss | $132.9 million | $129.5 million |
| Net loss | $128.5 million | $127.2 million |
| Net loss per share | $1.27 | $1.31 |
| Cash, cash equivalents and marketable securities at year-end | $189.8 million | $289.9 million |
| Net cash used in operating activities | $113.0 million | $98.9 million |
- Fourth-quarter 2016 revenue was $1.9 million and net loss was $32.3 million; fourth-quarter 2015 revenue was $1.8 million and net loss was $32.7 million.
- Revenue rose 24% year over year, mainly from collaboration, development, contract and grant activity; it was not product revenue. Gross margin is not meaningful for the reported business and is not presented.
- Operating loss widened 3% as operating expenses increased 3%; higher investment and other income partly offset this, leaving net loss up about 1% year over year. The 2016 increase in other income included $1.8 million from sale of New Jersey tax benefits.
- Working capital was $160.3 million, down from $264.7 million. Total liabilities were $117.9 million, including $44.2 million of Kolltan contingent consideration and $28.1 million of deferred tax liabilities. The filing does not identify conventional borrowings; interest expense was zero in 2016.
- Operating cash use increased by $14.1 million. Investing activities provided $68.9 million, largely reflecting net sales and maturities of marketable securities; financing provided $14.5 million, primarily from stock issuance. The company raised $13.9 million net through its Cantor at-the-market program.
Material changes and notable developments
- R&D expense was broadly stable, while program spending shifted: Rintega costs fell $19.9 million after its Phase 3 study was discontinued; spending increased for varlilumab and glembatumumab vedotin.
- The Kolltan acquisition was accounted for as a business combination. Celldex issued 18.3 million shares for the upfront consideration; the purchase-price allocation included $61.7 million of acquired in-process R&D and $82.0 million of goodwill. The allocation was preliminary.
- Celldex recorded $1.2 million of restructuring expense after deciding not to occupy Needham expansion space; it was seeking a subtenant.
- Common shares issued and outstanding increased from 98.7 million to 120.5 million during 2016. The filing reports 123.2 million shares outstanding on March 6, 2017.
Outlook, risks and contingencies
- Management expected continued operating losses and said 2017 cash use would remain broadly consistent, with program-level changes. It estimated that year-end liquidity plus anticipated Cantor proceeds could fund planned operations through 2018; separately, the financial statements state liquidity was expected to cover at least the next 12 months from their March 14, 2017 issuance. These estimates depend on financing and milestone-payment choices.
- METRIC, the Phase 2b glembatumumab vedotin study in triple-negative breast cancer, had a target enrollment of 300; Celldex expected enrollment completion by the end of September 2017. Fast Track designation does not assure approval. A companion diagnostic and commercial-ready supply were also in development.
- Management’s stated priority was to integrate Kolltan without increasing planned 2017 cash burn, while prioritizing programs and pursuing efficiency savings. Enrollment in the Phase 2 varlilumab/Opdivo study was expected to finish in Q1 2018.
- Kolltan’s merger agreement provides for contingent milestone payments of up to $172.5 million, payable in cash, stock or a combination, subject to agreement terms and Nasdaq rules. Celldex recorded a $44.2 million fair-value liability at year-end; payment timing and amount depend on milestone achievement. Stockholder approval may be needed for share issuance above applicable limits.
- Key risks include the clinical and regulatory uncertainty of the pipeline, ongoing capital needs and potential dilution, patient-enrollment and manufacturing delays, dependence on third-party suppliers and diagnostic collaborators, competitive pressure, and patent disputes. The European patent supporting varlilumab was revoked by the EPO; Celldex intended to appeal. The filing also describes a separate pending patent appeal that could affect CDX-3379 in Europe.
- Unusual clinical outcomes include discontinuation of the Rintega Phase 3 ACT IV study after interim analysis indicated it was unlikely to meet its overall-survival endpoint; the osteosarcoma study of glembatumumab vedotin did not meet its threshold to proceed to stage 2. Celldex reported no material legal proceedings and no off-balance-sheet arrangements.
- PwC issued an unqualified opinion on the financial statements and internal control over financial reporting; management and the auditor concluded controls were effective as of year-end.
Important facts for investors to verify
- METRIC enrollment timing, final efficacy and safety results, and the status and approval path of its companion diagnostic.
- Actual cash runway, financing raised after year-end, operating cash burn, and whether any Kolltan milestones become payable in cash or shares.
- Clinical progress and evidence supporting the acquired CDX-0158, CDX-3379 and TAM programs; monitor impairment assumptions for acquired R&D and goodwill.
- Manufacturing continuity for glembatumumab vedotin, including replacement supply arrangements, and the availability of key components and diagnostic partners.
- Developments in the varlilumab and CDX-3379 patent proceedings, potential dilution from equity issuance, and any restrictions on tax-loss carryforwards.